IMGN - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone and welcome to the First Quarter 2019 Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Sarah Kiely, Director of Investor Relations and Corporate Communications. Please go ahead.

Sarah Kiely

Good morning and thank you for joining today’s call. a progress that financial and issued of the results. we recent our first today, press includes release summary Earlier quarter XXXX be at immunogen.com. This the & a and section found can Media website press Investors under our recording of the release call of

our today Scientific Berkenblit, session. Officer; Officer, Foster, Chief Medical the and and call President will CEO; Gregory, Accounting team Q&A Mark Dave are On Officer. for join our Rich Enyedy, and Anna Chief Chief the the our our

we During progress, our call, recent today’s will highlight review first discuss and results upcoming quarter financial milestones.

use During SEC the the discussion, statements filings. will turn With investment in over actual we from an Descriptions with will results materially may that, Mark. of I such ImmunoGen associated statements. call forward-looking differ the are our our in to uncertainties and risks and included

Mark Enyedy

Thanks, us morning, cancer line FORWARD joining platinum-resistant mirvetuximab thank today. announced you from in In I the Sarah. for top everyone we X Phase of results March, Good and study patients. early ovarian

While efficacy disappointed were a alpha high primary receptor see its encouraged pre-specified to did endpoint, consistent trial we folate not that in of patients we the expression. subset with were signal meet the

chemotherapy, and comparison mirvetuximab we than in response more rate to Specifically, this patient the more twice with responses durable observed in population.

overall safety tolerability mirvetuximab. and demonstrate In the mirvetuximab-treated benefit longer with differentiated profile efficacy and were for addition, patients. progression-free consistent in a survival, coupled We believe signal, this risk favorable

FR updating discuss forward population. additional on path analyses the will our high registration with these the look the be discussions. of of from we to you clinical those We to in mirvetuximab I monotherapy to this benefit the the advisors, input quarter potential FDA outcome the for from regulatory alpha With of data FORWARD and and meeting

promising mirvetuximab and our will of opportunity from our upcoming FORWARD the with this to study. regimens we you mirvetuximab goal the on expanding progress for update trial, lines therapy. data combination Anna market with of have generated in Moving our II earlier data

label we an In combination a for mirvetuximab. approaches to support addition, as evaluating are independent avenue

we IMGNXXX, in hematological our mirvetuximab, IGN beyond programs, are novel Looking advancing malignancies. IMGNXXX and

with the and data completion plan We collaboration on year. this activities in in in this are AML Phase for we Separately, continue to ADC track our X BPDCN, ADAMX-targeting are expected cohorts refractory patients patients both a before for with IMGNXXX study the IMGNXXX and X relapsed with crew or novel studies later for for in nearing of Phase expansion patients, of of MacroGenics, of study with end IND-enabling AML our enroll we being IMGCXXX, submission that’s the XXX year. developed with of

for press review Turning announced flexibility which our expect in operational with were we financial results we providing the in on portfolio. in and investment cash ongoing, morning. previously results, to of business of financial the strong to the million balance engagement to effort following the extend ImmunoGen release sheet, this position is FDA. with the this our our detailed is $XXX approximately The our issued a continued runway announce

revenues generated noncash Kadcyla we financials, which million in in quarter first $X.X our revenue, related $X.X Regarding royalty million included sales. to

prior primarily current Our period the patient trial driven expenses for operating XXXX. were to same year million accrual quarter by expenses first $XX were these clinical I. compared decrease The in the with million the accelerating when cost for approximately FORWARD quarter was in to in $XX compared related the lower

balance equivalents the on with the As $XXX sheet. cash previously approximately in noted, and we ended cash quarter million

pipeline Anna call more review XXXX We I’ll to update on will provide an our progress that, guidance the the over review. completion following financial of operational detail. With our in our to Anna? turn

Anna Berkenblit

Mark. Thanks

of announced have As mirvetuximab FORWARD study Phase the I results from recently X line top we soravtansine. mentioned,

its remain folate meet While endpoint, prespecified encouraged signals we alpha efficacy the receptor are consistent by high we primary disappointed of the subset. study not that did in this

the initially consistency subsequently Additional the signals efficacy we we reinforced observed in line conducted analysis of results. the top

For or adverse and than modifications fewer dose X the greater mirvetuximab well treatment-related discontinuation is Grade events, tolerated, safety with chemotherapy. perspective,

with believe folate patients receptor of high population and X alpha recent a ovarian those a platinum-resistant profile benefit these For risk from chemotherapy. favorable demonstrate trials need, cancer, highlighted data we novel inhibitor by checkpoint a expression, disappointment a still has that in Phase unmet a high

clinical experienced investigators shared have regulatory data We FORWARD I additional and advisers. and the mirvetuximab with with

availability We hear to who option. tumor cancer cancer as give colon a and with monotherapy. be and therapy. disease ovarian such the to receptor treatment types, need mirvetuximab high platinum-resistant of more multiple of their of forward additional to effective context, other as to we that with know path able approval with regulators continue patients Within longer patients alpha well-tolerated effective forward a mirvetuximab physicians lines to that this discussing live for myeloma, look want folate we In

ESMO the year. to later present to and planning are data this data We submit the

Turning are the which lack in now to FORWARD to profile of we advancing lends combination, the trial. mirvetuximab, II combinations, the itself myelosuppression particularly tolerability of

Our plus as in combination goal II, triplet disease. agent with combination in Avastin are mirvetuximab at carboplatin In cancer, remains evaluating as platinum-sensitive use therapy. to patients and looking that lines earlier establish in well we ovarian supporting mirvetuximab FORWARD cohort recurrent doublets is of mirvetuximab choice of as the a

Christie data at combination through the the gemcitabine presenting mature her initial cancer Avastin from plus Also Dr. We ASCO, data NCCN. ASCO. present doublet cohort in trial mirvetuximab will will ovarian at be from platinum-resistant

we therapy. cohort, which after who ovarian as to the cancer. platinum-agnostic This second For triplet efficacy submit the are FORWARD maintenance Mark mirvetuximab number evaluates II growing initial includes ESMO. cohort, PARP planning in population to And enroll Avastin patients ongoing inhibitor the we data patients noted, to in platinum-agnostic of continue and safety progress

BPDCN. being earlier our the for AML portfolio, treatment are to our hematologic a these and IMGNXXX IGNs, with IMGNXXX, on Moving malignancies stage focus of novel evaluated and

and ADC. further XXX and in were lung, our at Europe CDXXX-targeting in deploys refractory from ADC for the showcasing while BPDCN study is cohort We XXX with of that non-small cancers present meeting. cell AML a continued X for Phase platform. presented ADC our the our AACR, most our as AACR patients Phase also colorectal and in In recent gastric sites Patient models research preclinical most with IMGNXXX our continues payload, in IGN opened reminder, additional candidate, to at at in pleased as being in As AML. annual is innovation our total, advancement encouraging study activity we of of the relapsed XX demonstrating posters well newest enrollment potent X expansion a CDXX-targeting or IMGNXXX IMGCXXX,

to before IMGCXXX of end we year. expect Mark an file the As for IND noted, the

Looking dosing BPDCN ahead, data with we this the additional establish Phase plan X AML to and and year. recommended schedule present updated IMGNXXX patients

We studies the the to call back establish with turn combination over X XXX will Phase dose for recommended will initiate I IMGNXXX. Mark. that, and With

Mark Enyedy

Anna. Thanks,

our platinum-resistant ovarian details not support a of generating that from top to line study opportunity while to label at FORWARD XXXX, our move executing EMA and we full and we a future an the discuss to our are potential we questions. approval first, the finally, for mirvetuximab ovarian to line With the operations path will include: avenue priorities, to that, medical cancer; position. completing continuing the FDA as which ADCs; additional preserve to today combination focused position the in we a independent data for of next-generation monotherapy portfolio everyone advance determine and cash goal forward as and results our remind with of remain in near-term As review have we I, to market cancer; in I a in a to a data present on disclosed working meeting. of order extending to with expansion open want

Operator

Instructions] today first Newman from comes Thank Our [Operator question you. John from Canaccord.

John Newman

Good questions. for morning. guys. Thanks Hey, taking much very my

have So, they the you if Mark wondered the expect curious going any to and similar might wonder that would regulator, FDA differences considerations in just Thanks. way perhaps that think the be just would there Anna, or I to if of things the terms there you with European interactions just that be about that forward? would approach in and plan

Mark Enyedy

Yes.

those ourselves. So have different find somewhat we to agencies assessing like circumstances approaches

our so for approvals the a endpoints. similar approvals for differs accelerated E the to, provision has is the And there avenue marketing called the subpart EMA, while FDA approach clear in surrogate And the agencies biologics considering a for related on authorization based degree. for very to some case, conditional to

us, implications one And so for is that, timing. as it the relates to of

be so time there longer than Europe, but And line with will our engagement FDA. engaging are we with the

that, Beyond differ. can differ endpoints data the approach can to full at look differently even and tend approval the surrogate to they also

for In endpoint example, Europe, is happy with So PFS survival perfectly a for full patient-reported support look outcomes, for they FDA for PFS, often approval. beyond as example, to finding. an progression-free

are approach, become as the framework well, said, I important. do so analogous details that general And broad the the

John Newman

the one just know of just Obviously, if Anna, speaking sort will of in were that for Okay, great. point. time, if that obviously, discuss events where data at the can’t you survival maybe survival but Thanks. just And you question time? give fell at just Thanks. get I this the out curious broadly full that can say there report, a on a wanted details we at the events sense initial number time later data us you would then meaningful

Anna Berkenblit

Right.

situation and platinum-resistant somewhere that in XX survival XX highlights is really dire are overall reminder, that these a patients as So ovarian in. cancer the months between

completed in You data that year, the year was timeframe. we in the months last of primary And between. in for March/April we analysis January cut the may approximately X this that recall enrollment so the trial in used

endpoint, period. past imagine, have will, potentially are with really overall can you especially who time many end enrollment median That brisk said, live that being we the for the median yet you survival. to had that opportunity patients enrolled over So XX-month a the very patients the there not if toward

a say hazard release a reported so would of ratio p-value in the on a we is number events. I And based with and ratio X.XXX press what reasonable hazard X.XX was that of of the

endpoint. and overall to key follow patients However, the which were data we continue survival, a is for immature secondary

John Newman

Great. Thanks so much, guys.

Operator

from our comes William Andy Hsieh question from next Moving Blair. on,

Andy Hsieh

that rolling. let’s that parts long take taking of meeting, in. event, scenario if so start negative questions. of fast-track Phase from a I can And am positive and event go study? how get you lay perspectives I just the FDA we the designation, ball out, realize in to second my of timing the I Thanks means for for of wondering that in you say, – various am wondering how can it would the kind when soon application you of kind the start a have X just start

Mark Enyedy

Yes.

positive the file the the to of able to So a before meeting, in the year. FDA BLA be of would expect event we end

the on is depend initiating a with the that for full of what dialogue some of requirements terms that’s to initial their In what study, their vis-à-vis and then and approval. perspective agency we confirmatory both have going are the application

little point. And bit time a hard so to at Andy, this that, it’s

I should the that discussion of think we wait them. have with outcome that the

Andy Hsieh

your it’s clinical like experts, if and curious just no, are kind some regulatory some experts, experts guess fair what I of at experts, that forward, Yes, these what high talk hesitation maybe maybe Okay. cause I in based aspects very about those? of discussions some we aspects high level, with are various terms level understand. can a a enough. recommending going And on on

Anna Berkenblit

we we safety that outside they the that subset, experts. subset, in we consistently And with consistency Sure. that the the have signals high of efficacy tolerability see the drug consultants Andy FR with profile. favorable differentiated will impressed start with coupled that the and development high the regulatory are clinical alpha are hear and engaged I experts things with include The

together, is favorable FR this package So, believe subset. there those you we risk when alpha in benefit a high

to we reminder, fewer price physicians Even how toxicity pay. this a signal had a reminder, went also we adverse agent is with use. active so as based that a chemotherapy due events. that, against there And efficacy another get drug-related know As on to adding didn’t we to that head-to-head discontinuations to

primary a have So benefit to that really does we given interpret is the how high clear from a Where perspective, it’s data benefit so trial the the conversation risk. Phase that favorable X goes then meet the from risk subgroup did endpoint. the not

we the well-tolerated effective data so we the in with these discuss And to more the regulators therapies, the data forward to context forward. looking patients path need platinum-resistant generated which given and discuss who are in

Andy Hsieh

I see.

taking for super helpful. very that’s Okay, Thank much you my questions.

Operator

on, RBC hear from Markets. will Kennen Capital Moving we MacKay from

Kennen MacKay

what you like with taking help EMA least path Hi table? mentioned And of progression, To for about when should potentially things is approval. this it’s analyses the has Kennen. we the full question. then the approach time clear there? is the for can to be be very sort meeting? in at an mentioned the were understand approach secondly, for additional Thanks are sort III is of taking that discuss that forward agenda that be same you’re Or Anna, you’ve aiming of You taking ahead us clear the conditional approval? second in you or for aiming And to U.S., the efficacy the on those encouraging. to maybe thinking you set accelerated this approval FDA Phase Thanks. the of end the meeting declared the something

Anna Berkenblit

plan. the data efficacy reported efficacy the analyses top So, in key in X statistical that prespecified analysis Kennen, additional terms line of were analyses, were the that we really March the

analysis that now so other there efficacy as plan, statistical those However, many gotten and well. data the were prespecified have in we were analyses

subgroup X, Specifically, describing, patient-reported also consistent. at ITT X our were also responses, to at patient again, outcome what X are high subsets. data we were prespecified to data, around at the X, analysis looking is so PFS X at looking also within progression-free And CA you looking FR which looking similar looking priors, XXX additional versus survival at alpha the subset, the and

So, this with in initially top really line a indicative the efficacy are of believe alpha that the subgroup. the is we FR data signal high data why consistent presented

U.S. forward Europe, question Turning respectively. that discussion regulators both those the authorization, and and around are reasonable we the in to with the approval path your of believe marketing conditional accelerated for

Kennen MacKay

That’s for the answering all. Thanks question.

Operator

next is from Guggenheim. Michael Our from Schmidt question

Michael Schmidt

the questions. Hi my just had guys. And some to comment data another just doing presentation? you whether made around wondering the a then, included if follow-up the FDA that Maybe Good comments the the just I in now heading on ESMO analysis and/or and morning. that for you follow-up analysis, before additional as taking Thanks will be was was would OS on the a OS just it I of well. be interesting

Anna Berkenblit

consented So, overall been we follow of that. to patients for for are are that they’ve we and type continuing And doing survival. follow-up,

Michael Schmidt

OS you for mature So, more FDA will meeting? your data have

Anna Berkenblit

data discussion the to regarding We forward. productive will FDA potential be will a providing that most the facilitate package path

Michael Schmidt

just Thanks. expectations terms us helpful. potentially looking that then at of data presentations you those very and then coming more for with patient example, respect of ESMO. Okay, for some are numbers, ASCO Could other just some of up, the you And in mentioned what and are give details interpretation updates data? to those

Anna Berkenblit

Sure.

we mature initial bevacizumab ASCO, data at cohort. Avastin will plus present our or mirvetuximab So, from

last recall XX was trial presented may You enrolling. still that ASCO, at we that year patients from a data on

Now from we have have They patients. data platinum-resistant disease. all XX complete

safety presenting entire be from that cohort. will we so, mature, And efficacy and data

year, the share remember, data December we Turning this at I so ESMO, submission, showing end carboplatin this we’ll the to at midst the ESMO, safety. data if Avastin, at is of enough are for triplets. triplet extremely we finalizing abstract FORWARD this well a is these first this with that mirvetuximab last and the in But plus do abstract of be accepted, triplet cohort rate The for and triplet in mature, both that. have with therapy completed for point, that the will for enrollment plus And long triplet, we survival. patients progression-free able be response to treated our

such we as so, any of data And event will PFS mature duration not response. time for to have even endpoint, or

Michael Schmidt

very Okay, you. Thank helpful.

Operator

Biren go we Amin And from Jefferies. will next to

Biren Amin

Thanks Yes, my questions. hi for taking guys.

guess, an you meeting? after minutes? the that you on it Would FDA when this would Mark, FDA update receive provide, Just meeting, I from be

Mark Enyedy

will course. the that be most I prudent think

would unambiguous, then us that communicate. the think the in for meeting I an opportunity to is unequivocal dialogue provide and if

complex there conversations written the benefit minuting the to the extent have more wait think that I might the to we would that probably are nuanced communication of agency. from then from benefit

Biren Amin

But the Got as through as data OS of patients? view PFS view and conference it. course think relates external data that they as relevant then, the the it communicated And advisers consistent. FR the your high clinically to I you’ve in this call, would

Anna Berkenblit

survival in that platinum-resistant ever median We I benefit unmet an somewhere really to this has do The for the our reason as we standard, between survival months. follow outcomes. longer. high and and I equally live And no overall demonstrated feel is cancer, ovarian and patients in patients survival. XX would as to monotherapy XX patient population and with overall need. better rate important Biren, that, that’s say And Yes. such is patient-reported the response important, is progression-free Ultimately, continue gold while overall including are characteristics argue other survival want

parameters that patients efficacy will to an suggest so who be armamentarium all important minds outcomes for our the the of currently. And with mirvetuximab we’ve at options limited have that far, poor looked in addition these

Biren Amin

And we data, I review, our the seen Alright. guess until from I guess, and ESMO. full haven’t then, won’t we

So, the I provide would where you there’s baseline imbalances across high arms? if guess, characterize with FDA meeting patients the full and FR data, in any you

Anna Berkenblit

in that the see that high subset, the ITT imbalances interpretation the looked analyses FR the Given alpha at population confound and of data. we’ve could do not glaring any we prespecified

Biren Amin

Great you. thank

Operator

Our next from Jonathan Leerink. question comes from SVB Chang

David Ruch

Jonathan. taking on Hi is David This for guys. my for questions. Thanks

on a your give alpha to guidance kind about without you’ve a how get you data, a to had little And into too any that FORWARD folate factor? this but changed wanted thinking look thinking the prognostic now bit chance general the how, at deep on the going further, as I receptor has data are Just opinion on of you that? can

Anna Berkenblit

that regard. the important some alpha X in that. quite folate in are remain in data that poor trial that receptor interested Phase we and from factor, I our say suggesting literature are there the data is prognostic a So, assessing would retrospective

We lower did patients we and alpha patients expression. enroll high FR expression. a negative or enroll reminder, not medium with a FR alpha with As

I as will And to done data so, help to be be there. alpha start our say I’d more there’s understand a FR prognostic folks think work important set but factor, to

The important point, factor a for benefit though, predictive is that mirvetuximab. from FR alpha is

David Ruch

Great. if about following like? folate you could what group? any And kind to could if forward the And that just us give potential you you’re path alpha high receptor about a just again, regulators, ask discussions of thinking how looks with bit tell wanted little

Mark Enyedy

before is, package, we the to So, given to year. receptive this this need and the be circumstances expect approval of if that obtain BLA file question the to data the think the expectation for timeframe FDA could I under in end priority I filing. unmet a follow they’re here, then If X our receptive reasonably X the review would is the would months’ after think application, so to a

So, that question? your answer does

David Ruch

helpful. more monotherapy, triplet, just That’s same clarify those events the Avastin Yes. And both if one just strategies as do adverse drops? could now, and for combo for then combination me, the the the eye you the have example, studies, for mitigation for the

Anna Berkenblit

yes, we data, plus we should as closed Yes, And I an well. And enrollment mention, currently that picked I do bit. actually should ongoing that and also they Avastin also announced enrolling I in a FORWARD after the combination do. have mirvetuximab cohort mention second has is up that

David Ruch

much the appreciate so Thanks and Great. follow-up.

Operator

Boris has next our from Cowen Peaker question.

Boris Peaker

Thanks. Great.

about mean, FORWARD further receptor set. probably on data the folate high just a So, we’ve patients. I I lot the talked

hazard physicians? hazard they to Can a lot folate there caused or but obviously on comment had a by disclosed used what subgroup medium that, could calculation haven’t on for you ratio that my why suggests receptor, relative that the data ratio. positive back the of You control a that positive have the expressers, was

Anna Berkenblit

we looked they higher that less shrinkage; data, paucity so hair all the alpha suggested felt more and were had as the two So, deeper a and no we safety designed of myelosuppression. and well at from reminder, mediums, they be two, tumor folate the the of in one, as did we neuropathy things: advantage trial, chemotherapy. receptor least loss, the with profile there that the durable like less of the relative expression, but terms could as the a data benefiting real when of we And mirvetuximab, a

would the that as do designed – felt the that at as was studies chemotherapy. when we likely it least again, we the So, well mediums

As you high to calculations, know really in FR the efficacy from the Boris, seems alpha your be subgroup.

And patients full data forward most mirvetuximab see to set, do data we a presenting submitting we benefit might are to likely path the exclude And select the look have so and who themselves who major can to a for not. forward everyone – those the at medical so from meeting. to

Boris Peaker

curious FDA if it. Can efficacy basis of was as the of analysis for subgroup? an a a subgroup signal approval you’ve study of there strong when you just Got done an accepted clear any kind think a example, has where a from that I’m

Anna Berkenblit

This that So, was what was a prespecified distinguishes this a post-hoc analysis. subgroup. not our study is

is did we the not we and designed endpoint However, for with this forward forward in FDA to on study meet based path why primary engaging approval. the look how this it,

Boris Peaker

comment many XXX, And AML relapsed/refractory how you how Great. just if on have curious on many just enrolled could to-date? lastly I’m you patients BPDCN and separately, patients

Anna Berkenblit

BPDCN the enroll data comment ASH can’t on AML I sharing both look year and patients, our abstract continued submitted. we since numbers, have if of the at end accepted and at to we after this exact is forward but ASH, we to

Boris Peaker

very much for Right. you my questions. taking Thank

Operator

next Fye JPMorgan. [Operator from comes Instructions] Jessica Our question from

Jessica Fye

Thanks questions. guys. morning, for my Good Great. taking

trying that’s something ASH of is understand expect could the for to dose, if moving to thought update you was was share to kind a prior approval? go-forward help to or up the select the it can along when person nicely should question, to able I hear that think we we just specifically you be next data pre-specified extent might that on say we when see represented that update? XXX, And the can Just the you a interesting. about subgroup where us there think then Is that on last there following of basis more

Anna Berkenblit

Yes.

that details, precedence. a where precedence, point regulatory get outcome. were for despite one negative a a regarding approval I pre-specified was regulatory as share there I subset they the in but to in not to So, pemetrexed, you I’m direction do able would believe able

could repeat sorry? question, you XXX, Regarding the

Jessica Fye

data next update, just selection the a for to of best of which potential about be the prior for seeing was It kind go-forward dose progress as the hear would December? to us like data actually point Yes. guess

Anna Berkenblit

don’t think commit can a combination start this to work we timeline, I we XXX year. are with but to planning

Jessica Fye

Okay, thank you.

Operator

from Debjit comes question from next Wainwright. Our H.C. Chattopadhyay

Debjit Chattopadhyay

morning. good Hey,

all you at So, be Mark you because the least was – combination PFS, in mentioned, the PRO patients I need historically, it PRO the collected prospectively? in acceptable? is reason And of ask plus would a EMA

Anna Berkenblit

Debjit. and We study – the bevacizumab from prespecified is a where Yes, it abdominal they on an that improvement when of you subscale and XX used tool add in than PRO had present data than endpoint article based six-question We the greater same secondary subset was of AURELIA used showing Stockler, key that was There XXXX a PROs. by in that JCO the GI from AURELIA the chemotherapy symptoms. points greater the and there chemotherapy, is in to with sorry, XX% compare study.

patients So, did who chemo key felt they in on symptoms focused the than and questions from chemotherapy. bevacizumab cancer, that got other six better, really are better words,

to PRO to same the set and data medical a sharing at our applied meeting. data we So, future forward analysis those look we

Debjit Chattopadhyay

AURELIA to criteria, that an an similar patients abdominal how from bleeding just perspective closely So, enrollment from to perspective? risk at events? the Was Anna, are exclusion for clarify, exclusion the

Anna Berkenblit

looked monotherapy chemotherapy. mirvetuximab trial Our versus monotherapy at

relevant trial, the Avastin So, were exclusion Debjit. our for really for not criteria

risk based at are So, regimen. should or bleeding perforation tumor Avastin-containing really not on patients get their abdominal who on for

that. but everyone, more out, to in around point – options. need do priors, with specifications Avastin So, is fact, patients so in you as we not X for X had it’s And appropriate no trial, approved for we chemotherapy our

Debjit Chattopadhyay

there investigators, months, are that trend And greater X it? it’s Great. a may in especially months indication, increased discussions it say from Is was powered a then though – with to this they how stats overall towards there’s or is for if there even than – are it the clinically study X.X survival not your your – relevant X defining the benefit? not given plenty

Anna Berkenblit

Yes.

really survival, is how So, exactly, and long rate, it’s from our view effect a they the is they benefiting, feel response they who of do PFS price benefiting, overall the perspective, what are totality where how overall it’s are data right? side that paying

Debjit Chattopadhyay

one last just So, follow-up.

or advocate, to just on would in you in would X given questions? Avastin with to another that proceeding seeing benefits with much. a a your BLA triplet in devil’s a you is X the versus So, – the as during so or single-agent filing, mentioned prepared Thank there you’re X playing remarks pushback the case you combination uniform pivot in case study consider you and

Mark Enyedy

Yes.

the of view different us that set think of totality then their the gives drives on think on I have I path. And looks one those it’s identify about hand, say with FR prespecified are compelling – what data going If this in considerations. good, is data a depend that to existing – subset to to regulators other the think down study patients, data FDA us alpha but We if able want see patients a of more to high. were set. the the don’t those

– point with say. will say they is, so we at I have to studies. it forward think And What this we that’s on can moving what depend are combination

that by We’re and those continue we data will encouraged work.

Debjit Chattopadhyay

much luck. and you Thank good so

Mark Enyedy

you. Thank

Operator

appears Speakers, it turn I’ll you. this time. are to back questions conference no the And there further at Instructions] [Operator

Mark Enyedy

look Great. you our and your Thanks. Thank ASCO. you. much you forward We all our and at of to discussions progress, to quarter up-to-date very time keeping this on regulatory including outcome appreciate the seeing

Operator

today. Thank participation. our for conclude conference that you And your does

may You now disconnect.

Immunogen (IMGN) 3 May 192019 Q1 Earnings call transcript